Dr. Weirong Kang, Ph.D.
Dr Kang received her Bachelor of Pharmacy degree (B.Pharm) with Honours from China Pharmaceutical University in 2013. She then joined the School of Pharmacy in the University of Auckland, New Zealand for her PhD project under the supervision of Prof Zimei Wu. She was the winner of the 2017 Controlled Release Society (CRS) Young Scientist Awards.
Her PhD research has focused on developing nano drug delivery systems that can actively target the biomarkers in malignant tumours for precise cancer therapy. In her PhD study, she has developed peptides functionalised liposomal systems to selectively deliver boron compounds to glioblastomas and therefore enhance the efficacy of boron neutron capture therapy (BNCT).
After completion of her PhD degree, Dr Kang continued her research in cancer therapy in Gu Lab at Hong Kong Baptist University. In Gu Lab, she is currently working on cell adhesion and cell signaling in triple-negative breast cancer.
Kang W, Svirskis D, Sarojini V, McGregor AM, Bevitt J, Wu Z*. Cyclic-(RGDyC)-liposomes for dual-targeting tumour vasculature and cancer cells in glioblastoma. Oncotarget. 8, 36614-27.2017
Kang W, Svirskis D, Wu Z. Liposome based boron neutron capture therapy for brain glioma: Current and future perspectives (Chapter 11). In Benjamin R Pearson (ed.) Liposomes: Historical, Clinical and Molecular Perspectives. Nova Science Publishers, Inc. NY, p317-42. 2017